Curaleaf Responds to Aurora Circular; Reaffirms Offer as the Best Path to Value Creation for Shareholders

Curaleaf pushed back against Aurora’s board and reiterated its offer, highlighting a 45% premium to Aurora’s unaffected price (and 110% excluding cash) plus an implied CY2026E Adj. EBITDA multiple of 12.0x, stated to be ~68% above comparable Canadian peers. Curaleaf argues Aurora’s fundamentals have deteriorated—guidance calls for fiscal 2027 revenue back near fiscal 2025 levels, adjusted EBITDA expected to decline sharply, June quarter operating cash flow turned negative (C$4.4m)—and that Aurora has enabled further equity dilution via its ATM program (US$398m raised since Sept 2020; ATM sales at average prices of US$3.57 and US$3.09). Curaleaf counters by citing stronger cash generation (US$145m operating cash flow LTM through June 30, 2026), better leverage trajectory, and its ability to raise US$500m senior secured notes, while pointing to regulatory developments that reduced 280E-related uncertain tax position accruals.

Analysis

This is less a valuation argument than a capital-allocation referendum: the market is being asked to reprice a chronic cash consumer against an operator with access to debt and positive cash flow. The second-order winner is the whole class of cannabis platforms that can self-fund; if the bid process advances, balance-sheet quality should matter more than nominal growth, and that pressures every issuer still leaning on ATM capacity. For Aurora, any rally tied to the offer is fragile unless it is accompanied by a verifiable change in financing behavior, not just rhetoric.

The immediate tape reaction is likely driven by deal probability, but the 1-3 month catalyst is whether Aurora engages, requests a sweeter structure, or stays in standoff mode. If the board refuses talks, the stock can quickly revert to its dilution discount because the market will re-anchor on runway and cash burn, not headline premium. Conversely, Curaleaf’s upside is more limited: if investors conclude it is paying for optionality rather than cash flow, the acquirer multiple can compress even if the target gaps up.

The contrarian miss is that the real asset being priced here is financing access, not cannabis exposure. The market may be underestimating how punitive the sector becomes when the strongest issuer can borrow institutionally while weaker peers are still selling equity; that widens the performance gap over 6-18 months. Falsifiers are straightforward: a credible counterbid, a withdrawal/sweetening of the ATM overhang, or evidence that Aurora can actually stabilize revenue and EBITDA without fresh dilution.

Key Decisions for Investors

• Long ACB on any post-release weakness if it trades materially below the implied deal value; use a 1-3 month horizon and take profits once the spread tightens, because upside is event-driven while downside reopens quickly if talks stall.
• Short CURLF/CURA into strength as a small-size event hedge, with the thesis that the market may be overpaying for consolidation optionality; cover if Curaleaf prints another quarter of positive operating cash flow and de-leverages as guided.
• Pair trade: long ACB / short CURLF in dollar-neutral size for 4-8 weeks if you expect a negotiated process; this expresses target upside while hedging broad cannabis beta. Falsify if Aurora formally rejects talks and no counter appears within a month.
• Set an alert for any Aurora disclosure on ATM suspension, financing, or special-committee engagement; those are the real catalysts that would convert this from a PR-driven move into a durable rerating.